Serial Ultrasound of Solid Tumor Lesions to Detect Early Response to Cancer Immunotherapy
NCT ID: NCT05206942
Last Updated: 2025-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2022-03-21
2026-02-28
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Secondary objectives are to evaluate if there is an optimal ultrasound imaging modality (CEUS or conventional power Doppler or LEAD ultrasound) or optimal time point to predict initial objective response and to assess the correlation of tumor perfusion parameters with change in overall tumor burden, change in diameter on a per-lesion basis, and with 12-month progression-free survival (PFS).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Sub-regional Tumor Segmentation Based on CEUS Perfusion Characteristics: Enhancing Breast Tumor Diagnosis
NCT06172270
Sonazoid-Enhanced Ultrasound in Detecting Sentinel Lymph Node in Patients With Cutaneous Melanoma
NCT02968680
Clinical Application of Super-resolution Ultrasound(SR-US) Imaging in Solid Tumors
NCT06018142
Feasibility of a Minimally Invasive Thoracoscopic Ultrasound for Localization of Pulmonary Nodules
NCT02665078
A Trial on Contrast-enhanced Ultrasound Versus Conventional Ultrasound Guided Biopsy of Liver Neoplasms
NCT02413437
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Ultrasound
Patients receiving standard of care immune checkpoint inhibitor are followed with the ultrasound studies at treatment baseline, 3 weeks and 6 weeks.
Doppler ultrasound
Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
Contrast-enhanced ultrasound (CEUS)
Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Doppler ultrasound
Power Doppler measurements will be made using a portable Siemens S2000 or S3000 ultrasound scanner
Long Ensemble Angular-coherence Doppler [LEAD] ultrasound
Long Ensemble Angular-coherence Doppler measurements will be made using a Verasonics Vantage 256 scanner
Contrast-enhanced ultrasound (CEUS)
Contrast-enhanced ultrasound measurements will be made using Lumason IV contrast injection followed by an injection of normal saline
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* at least one solid tumor lesion greater than 1 cm in diameter (primary tumor and/or at metastatic site), amenable to ultrasound imaging
* planned to be treated with ICI therapy (single agent or in combination with any other drug)
* written informed consent.
* prior use of any ICI is not necessarily excluded, and patients may be included with the approval of the Protocol Director
Subjects may participate in the study more than once at the discretion of the Protocol Director, for example, if they receive different lines of treatment that all qualify for the study.
Exclusion Criteria
* any comorbid condition that, in the opinion of the treating provider or the Protocol Directors, compromises the participant's ability to participate in the study
* Examples: any mental condition that compromises the ability to follow a consent discussion, or to make informed decisions (except if represented by a Legally Authorized Representative \[LAR\]), or to have ultrasound exams.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institutes of Health (NIH)
NIH
National Cancer Institute (NCI)
NIH
Stanford University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alice C. Fan, MD
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Jeremy Dahl, Ph.D
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Aya Kamaya, M.D
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Stanford
Palo Alto, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2022-02835
Identifier Type: REGISTRY
Identifier Source: secondary_id
IRB-59526
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.